TY - JOUR
T1 - SCN3A-Related Neurodevelopmental Disorder
T2 - A Spectrum of Epilepsy and Brain Malformation
AU - Zaman, Tariq
AU - Helbig, Katherine L.
AU - Clatot, Jérôme
AU - Thompson, Christopher H.
AU - Kang, Seok Kyu
AU - Stouffs, Katrien
AU - Jansen, Anna E.
AU - Verstraete, Lieve
AU - Jacquinet, Adeline
AU - Parrini, Elena
AU - Guerrini, Renzo
AU - Fujiwara, Yuh
AU - Miyatake, Satoko
AU - Ben-Zeev, Bruria
AU - Bassan, Haim
AU - Reish, Orit
AU - Marom, Daphna
AU - Hauser, Natalie
AU - Vu, Thuy Anh
AU - Ackermann, Sally
AU - Spencer, Careni E.
AU - Lippa, Natalie
AU - Srinivasan, Shraddha
AU - Charzewska, Agnieszka
AU - Hoffman-Zacharska, Dorota
AU - Fitzpatrick, David
AU - Harrison, Victoria
AU - Vasudevan, Pradeep
AU - Joss, Shelagh
AU - Pilz, Daniela T.
AU - Fawcett, Katherine A.
AU - Helbig, Ingo
AU - Matsumoto, Naomichi
AU - Kearney, Jennifer A.
AU - Fry, Andrew E.
AU - Goldberg, Ethan M.
N1 - Publisher Copyright:
© 2020 American Neurological Association
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Objective: Pathogenic variants in SCN3A, encoding the voltage-gated sodium channel subunit Nav1.3, cause severe childhood onset epilepsy and malformation of cortical development. Here, we define the spectrum of clinical, genetic, and neuroimaging features of SCN3A-related neurodevelopmental disorder. Methods: Patients were ascertained via an international collaborative network. We compared sodium channels containing wild-type versus variant Nav1.3 subunits coexpressed with β1 and β2 subunits using whole-cell voltage clamp electrophysiological recordings in a heterologous mammalian system (HEK-293T cells). Results: Of 22 patients with pathogenic SCN3A variants, most had treatment-resistant epilepsy beginning in the first year of life (16/21, 76%; median onset, 2 weeks), with severe or profound developmental delay (15/20, 75%). Many, but not all (15/19, 79%), exhibited malformations of cortical development. Pathogenic variants clustered in transmembrane segments 4 to 6 of domains II to IV. Most pathogenic missense variants tested (10/11, 91%) displayed gain of channel function, with increased persistent current and/or a leftward shift in the voltage dependence of activation, and all variants associated with malformation of cortical development exhibited gain of channel function. One variant (p.Ile1468Arg) exhibited mixed effects, with gain and partial loss of function. Two variants demonstrated loss of channel function. Interpretation: Our study defines SCN3A-related neurodevelopmental disorder along a spectrum of severity, but typically including epilepsy and severe or profound developmental delay/intellectual disability. Malformations of cortical development are a characteristic feature of this unusual channelopathy syndrome, present in >75% of affected individuals. Gain of function at the channel level in developing neurons is likely an important mechanism of disease pathogenesis. ANN NEUROL 2020;88:348–362.
AB - Objective: Pathogenic variants in SCN3A, encoding the voltage-gated sodium channel subunit Nav1.3, cause severe childhood onset epilepsy and malformation of cortical development. Here, we define the spectrum of clinical, genetic, and neuroimaging features of SCN3A-related neurodevelopmental disorder. Methods: Patients were ascertained via an international collaborative network. We compared sodium channels containing wild-type versus variant Nav1.3 subunits coexpressed with β1 and β2 subunits using whole-cell voltage clamp electrophysiological recordings in a heterologous mammalian system (HEK-293T cells). Results: Of 22 patients with pathogenic SCN3A variants, most had treatment-resistant epilepsy beginning in the first year of life (16/21, 76%; median onset, 2 weeks), with severe or profound developmental delay (15/20, 75%). Many, but not all (15/19, 79%), exhibited malformations of cortical development. Pathogenic variants clustered in transmembrane segments 4 to 6 of domains II to IV. Most pathogenic missense variants tested (10/11, 91%) displayed gain of channel function, with increased persistent current and/or a leftward shift in the voltage dependence of activation, and all variants associated with malformation of cortical development exhibited gain of channel function. One variant (p.Ile1468Arg) exhibited mixed effects, with gain and partial loss of function. Two variants demonstrated loss of channel function. Interpretation: Our study defines SCN3A-related neurodevelopmental disorder along a spectrum of severity, but typically including epilepsy and severe or profound developmental delay/intellectual disability. Malformations of cortical development are a characteristic feature of this unusual channelopathy syndrome, present in >75% of affected individuals. Gain of function at the channel level in developing neurons is likely an important mechanism of disease pathogenesis. ANN NEUROL 2020;88:348–362.
UR - http://www.scopus.com/inward/record.url?scp=85087727204&partnerID=8YFLogxK
U2 - 10.1002/ana.25809
DO - 10.1002/ana.25809
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 32515017
AN - SCOPUS:85087727204
SN - 0364-5134
VL - 88
SP - 348
EP - 362
JO - Annals of Neurology
JF - Annals of Neurology
IS - 2
ER -